Endotherapia

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)


Volume 15, 3 Issues, 2016


Download PDF Flyer




Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Claudiu T. Supuran
Neurofarba Department
University of Florence
Florence
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Endotherapia



Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 9(3): 197-211.

Author(s): Michel Geffard, Laetitia de Bisschop, Sebastien Duleu, Olivier Pouns, Guillaume Ferran, Alban Bessede, Nadine Hassaine, Jean-Louis Autran, Dominique Bodet, Arturo Mangas and Rafael Covenas.

Affiliation: Institute for Development of Research on Human Pathology and Therapeutics (IDRPHT), 200 avenue de Thouars, 33400-Talence, France.

Abstract

Endotherapia is a new therapeutic approach against chronic diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and rheumatoid arthritis. It combines the evaluation of circulating antibodies directed against specific self-antigens and self-antigens modified by free radicals. Here, we review the literature concerning this topic. In addition, our biological assays have allowed us to follow up the evolution of chronic diseases along time, checking remission phases. For more than 25 years, our scientific group has suggested that the chronicity of diseases may be due to nonpathological bacteria living in different biotopes. Endotherapia is the result of immunopathologic work addressing chronic incurable diseases with a multifactorial etiology. Several genes are susceptible to toxic environmental immunologic agents. Thus, the intestinal ecosystem plays an important role in these mechanisms. Therapy is a “tailor-made” combination (MG1/RA, GEMSP) of the small molecules (e.g., vitamins … ) linked to poly-L-lysine (PLL). Each individual linkage to PLL offers great advantages owing to the chemical characteristics of PLL (e.g., non-immunogenic), increasing the half-life of the active PLL derivatives. Clinical trials have enabled us to confirm very good safety. Our results confirm the efficacy of the approach and we believe that it could be very promising for chronic diseases.

Keywords:

Endotherapia, clinical trials, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis, Poly-L-Lysine, MG1/RA, GEMSP.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 9
Issue Number: 3
First Page: 197
Last Page: 211
Page Count: 15
DOI: 10.2174/1871523011009030197
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science